Arsenal Bio: Cutting Staff by Half, Not Cells
Arsenal Bio, one of the rare cell therapy companies still swimming in a sea of failed raises, just laid off nearly half its staff. In a sector where funding looks like a unicorn spotted only in biotech myths, Arsenal Bio managed to raise some capital before executing a harsh 50% staff cull. It’s like hosting a party because you found chips, then eating all the guests. This bittersweet survival dance highlights the brutal biotech winter, reminding us that while cells might fight disease, companies clearly don’t fight layoffs. Half the team out, capital precious: Arsenal Bio’s 2024 cell saga, minus the happy ending.
Share the Story
(1 of 3)When your company is 'one of the few able to raise funds' but still chops half your team, your business model is basically survival-of-the-fittest meets corporate Hunger Games.
Arsenal Bio raised cash but still slashed half the staff. Nothing says 'biotech innovation' like 'hope you like unemployment.'
Cell therapy startup Arsenal Bio proves even in science, you’re half as likely to keep your job as to get stem cells.
Source: Statnews | Published: 9/17/2025 | Author: Jason Mast
More Articles in Business
Doom Devs Drop Hellfire Expansion While Xbox Drops Entire Team
South Korean Chipmaker Raises $26.5B While AI Gobbles All The RAM
Tesla Laughs as Other Automakers Slam Doors on EVs, Ride Gas Price Rollercoaster
NYC Hotel’s Kitchen Uses 2,000 Eggs Weekly to Feed Masses, Not Chickens
MrBeast's Candy Empire Faces Sugar Crash, Now Selling Ethics Instead of Joy
Man Trades Time For Money Then Tries To Retire Before Age 30, Shockingly
